Arrowstreet Capital’s ProKidney PROK Stock Holding History

Arrowstreet Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,202	Closed	-$70K	–	1530
2023 Q3	$70K	Buy	+15,202	New	+$146K	﹤0.01%	1222

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital's PROK Position: Q4 2023 in Review

Arrowstreet Capital sold out of ProKidney (PROK) in Q4 2023, closing a stake of 15,202 shares — an estimated $70K sold.

Arrowstreet Capital first reported a position in PROK in Q3 2023 and held it in 1 quarter. The position peaked at $70K in Q3 2023. 61 funds tracked by Wall St. Rank hold PROK as of Q4 2023.

Arrowstreet Capital reported no remaining ProKidney position as of Q4 2023 after selling out during the quarter.
Arrowstreet Capital sold 15,202 ProKidney shares in Q4 2023, an estimated $70K.
Arrowstreet Capital first reported a position in ProKidney in Q3 2023 and held it in 1 quarter.
Arrowstreet Capital's ProKidney position peaked at $70K in Q3 2023.
61 funds tracked by Wall St. Rank held ProKidney as of Q4 2023.

Based on Arrowstreet Capital's 13F filing for Q4 2023, filed 14 Feb 2024.